The Cigna Group Earnings Call Transcripts
Fiscal Year 2026
-
A major transition to a rebate-free PBM model is underway, with full scaling expected by 2028 and profitability aligning with legacy models by 2029. Specialty business continues to drive growth, while AI and analytics are delivering operational efficiencies and improved patient outcomes.
-
Q1 2026 saw strong revenue and EPS growth, prompting a raised full-year outlook. Specialty and Care Services led segment gains, while investments in the Signature model and portfolio reshaping—including exiting the individual exchange and reviewing EviCore—support future growth.
-
The meeting reviewed strong 2025 financial results, major investments, and a CEO transition. All board nominees and management proposals were approved, while a shareholder proposal on written consent was rejected. Strategic initiatives focused on affordability and transparency.
-
Strong 2025 results set the stage for continued EPS growth and robust cash flow in 2026. Major investments support a new rebate-free PBM model, driving transparency and affordability, while specialty pharmacy expansion and biosimilar adoption fuel long-term growth.
Fiscal Year 2025
-
Delivered 2025 adjusted revenue of $275B (+11%) and EPS of $29.84 (+9%), with strong growth in specialty pharmacy and successful FTC settlement. 2026 guidance includes at least $30.25 EPS and $280B revenue, with continued investment in innovation and affordability.
-
Strong Q3 results and reaffirmed EPS guidance set the stage for a major shift to a rebate-free PBM model, with investments in technology and analytics through 2027. Large client renewals provide stability, while the new model aims to simplify pricing, enhance transparency, and address regulatory concerns.
-
Q3 2025 saw strong revenue and EPS, with reaffirmed full-year guidance and robust segment performance. Strategic investments, a new rebate-free pharmacy model, and major client renewals position the company for long-term growth, despite near-term margin pressure in pharmacy benefit services.
-
Reaffirmed strong EPS outlook and highlighted consistent growth across health benefits, pharmacy, and specialty care platforms. Expanded specialty drug market presence with a $3.5B Shields investment, advanced biosimilar adoption, and maintained high PBM retention. Focused on bolt-on M&A, AI innovation, and adapting to regulatory changes.
-
Q2 2025 saw $67.2B in revenue and $7.20 adjusted EPS, with strong growth in Evernorth and reaffirmed full-year guidance. Specialty pharmacy, biosimilars, and GLP-1 innovations drove results, while cost pressures and regulatory activity remain key risks.
-
Q1 2025 delivered strong revenue and EPS growth, prompting a raised full-year outlook. Evernorth and Cigna Healthcare segments both posted double-digit growth, with new GLP-1 and biosimilar initiatives supporting future expansion. Capital management remains disciplined.
-
The meeting reviewed strong 2024 financial growth, major strategic initiatives in biosimilars and global expansion, and approved all management proposals, including director elections and executive compensation. A shareholder proposal on special meeting rights was not approved.
-
Challenging stop-loss results in late 2024 led to corrective actions and updated 2025 pricing. Specialty pharmacy and PBM remain growth engines, with biosimilars and GLP-1 programs driving innovation. Capital deployment will balance M&A and share repurchases.
Fiscal Year 2024
-
Full-year 2024 revenue grew 27% to $247B, with adjusted EPS up 9% to $27.33, but short of expectations due to stop-loss medical costs. 2025 guidance targets at least $252B in revenue and $29.50 EPS, with margin recapture expected by 2027.
-
Third quarter results showed strong revenue and EPS growth, led by Evernorth's specialty and biosimilar adoption, and solid Cigna Healthcare performance. 2024 guidance was reaffirmed, with 2025 EPS growth expected at least 10%, supported by innovation and capital deployment.
-
Specialty drugs are rapidly increasing as a share of healthcare costs, with significant growth driven by innovation and biosimilars. The organization leverages clinical specialization, operational scale, and broad market access to lead in both pharmacy and medical benefit spaces, offering substantial savings and value to clients and patients.
-
The conference highlighted strong, diversified growth across healthcare benefits, specialty, and pharmacy services, with innovation in biosimilars and GLP-1 programs. Evernorth and specialty segments are expanding, while disciplined capital deployment supports ongoing EPS growth and shareholder returns.
-
Q2 2024 saw 25% revenue growth and 10% adjusted EPS growth, driven by strong results in Evernorth and Cigna Healthcare. Full-year guidance for adjusted EPS of at least $28.40 was reaffirmed, with continued focus on specialty drug growth, biosimilars, and integrated care solutions.
-
Full-year EPS guidance was reaffirmed and capital deployment is focused on share repurchases, with at least $5B targeted in the first half. Specialty pharmacy and select segment growth remain key priorities, while government and exchange businesses are being repositioned. Utilization and cost trends are tracking expectations.